ARV-393
Product Specifications
UNSPSC Description
ARV-393 is an orally active PROTAC that utilizes the ubiquitin-proteasome system to target the degradation of BCL6. ARV-393 consists of ligand conjugates targeting BCL6 and the E3 ligase cereblon, respectively. ARV-393 has DC50 and GI50 values of <1 nM in multiple cell lines of diffuse large B-cell lymphoma (DLBCL) and Burkitt lymphoma (BL). ARV-393 also demonstrated considerable tumor suppressor activity in tumor xenograft models. ARV-393 is being studied to inhibit non-Hodgkin lymphoma.
Target Antigen
BCL6; PROTACs
Type
Reference compound
Related Pathways
Immunology/Inflammation;PROTAC
Applications
Cancer-programmed cell death
Field of Research
cancer
Assay Protocol
https://www.medchemexpress.com/arv-393.html
Solubility
DMSO : 11.67 mg/mL (ultrasonic;warming;heat to 60°C)
Smiles
ClC1=CN=C(N2CCC(O[C@@H]3C[C@@H](N4CCC(C5=C(F)C(CN(C6CCC(NC6=O)=O)C7=O)=C7C=C5)CC4)C3)CC2)N=C1NC8=CC(C=C(OCC(NC)=O)C(N9C(C)C)=O)=C9C=C8
Molecular Weight
898.42
References & Citations
[1]Sherman D. Abstract ND05: The discovery of ARV-393, a potent, orally bioavailable BCL6 targeting PROTAC® for the treatment of Non-Hodgkin’s Lymphoma[J]. Cancer Research, 2024, 84(7_Supplement): ND05-ND05.
Shipping Conditions
Room Temperature
Product Datasheet
http://file.medchemexpress.com/batch_PDF/HY-158105/ARV-393-DataSheet-MedChemExpress.pdf
Product MSDS
http://file.medchemexpress.com/batch_PDF/HY-158105/ARV-393-SDS-MedChemExpress.pdf
Clinical Information
Phase 1
CAS Number
2851885-95-3
Available Sizes
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
